The UK and US have secured a important bilateral deal that will ensure zero duties on British medicine products going into the American market.
Agreement Details of the Pact
As part of the deal, the UK has pledged to increase spending on pharmaceuticals through the National Health Service (NHS). This move secures that tariffs on these crucial products will be held at zero for a period of three years.
This deal comes after earlier threats to hike tariffs on branded drug products, with increases mentioned reaching double the cost.
"This agreement with the Britain strengthens the worldwide climate for cutting-edge drugs and introduces long-overdue fairness to transatlantic drug exports," an announcement noted.
Trade Significance
Pharmaceuticals represent one of the UK's biggest export categories to the United States, which is clearly the largest destination for major companies like GSK and AstraZeneca.
Export figures indicate that in the year prior to the third quarter, the UK shipped pharmaceutical products totaling £11.1bn to the US. This figure made up a significant portion of British export trade in that period.
"This guarantee secures jobs, stimulates capital expenditure and facilitates the UK to become a worldwide center for biotech and pharma," a minister remarked.
Specific British Pledges
The deal involves several specific pledges from the United Kingdom:
- Revised Affordability Limit: The UK will raise the affordability limit at which it deems new therapies to be unaffordable by 25%.
- Increased NHS Spending: There is a target to double overall health service expenditure on treatments from 0.3 percent of Gross Domestic Product to 0.6% over the following ten-year period.
- Rebate Cap: The amount drug companies must pay back to the NHS to prevent overspending will be restricted at fifteen percent. Previously, repayments topped 20%.
Industry Background
This agreement comes amid a long-running tension between the sector and the ministers over medicine costs and approval rates.
These tensions were intensified by claims that US customers were paying a premium for the same drugs than consumers in the UK and Europe.
Recently, several major drug company projects in the UK have been halted or scrapped, while substantial expansions have been directed toward US facilities.
The Science Minister stated that the NHS had to spend more on drugs, noting that its budget allocation on drugs had declined as a percentage of its total funding over the previous ten-year period.
